Oragenics Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Oragenics Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial and operational status.</b>

AI Summary

ORAGENICS INC (OGEN) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Oragenics Inc. filed a 10-Q report for the quarterly period ended March 31, 2024. The filing covers the period from January 1, 2024, to March 31, 2024. The company's fiscal year ends on December 31. Oragenics Inc. is incorporated in Florida. The company operates in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking ORAGENICS INC, this filing contains several important signals. This 10-Q filing provides investors and stakeholders with the latest financial performance and operational updates for Oragenics Inc. during the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential future performance in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — ORAGENICS INC shows moderate risk based on this filing. The company's financial performance and future prospects are subject to the inherent risks of the pharmaceutical industry, including regulatory hurdles, market competition, and the success of its product pipeline, as indicated by its SIC code and the nature of a 10-Q filing.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand Oragenics Inc.'s performance and outlook.

Key Numbers

• 2024-03-31 — Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-05-15 — Filing Date (FILED AS OF DATE)
• 1231 — Fiscal Year End (FISCAL YEAR END)
• FL — State of Incorporation (STATE OF INCORPORATION)
• 2834 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)

Key Players & Entities

• ORAGENICS INC (company) — FILER
• 10-Q (document) — FORM TYPE
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT
• 2024-05-15 (date) — FILED AS OF DATE
• FL (location) — STATE OF INCORPORATION
• 2834 (industry_code) — STANDARD INDUSTRIAL CLASSIFICATION
• 1990 MAIN STREET SUITE 750 SARASOTA FL 34236 (address) — BUSINESS ADDRESS
• 8132867900 (phone) — BUSINESS PHONE

FAQ

Industry Context

Oragenics Inc. operates within the Pharmaceutical Preparations industry, which is characterized by extensive research and development, regulatory oversight, and market competition.

Regulatory Implications

Companies in the pharmaceutical sector are subject to stringent regulations from bodies like the FDA, impacting drug development, approval, and marketing processes.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and profitability.
2. Review the Management's Discussion and Analysis (MD&A) for insights into operational performance and future outlook.
3. Examine any disclosed risk factors or legal proceedings that could impact the company.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-15: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial 10-Q filing for the fiscal year 2024, following the 2023 annual report.

Key Financial Figures

• $0.001 — were 4,480,693 shares of Common Stock, $0.001 par value, outstanding. Note Regardin

Filing Documents

• form10-q.htm (10-Q) — 718KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 10KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-24-019655.txt (&nbsp;) — 3102KB
• ogen-20240331.xsd (EX-101.SCH) — 27KB
• ogen-20240331_cal.xml (EX-101.CAL) — 35KB
• ogen-20240331_def.xml (EX-101.DEF) — 71KB
• ogen-20240331_lab.xml (EX-101.LAB) — 220KB
• ogen-20240331_pre.xml (EX-101.PRE) — 158KB
• form10-q_htm.xml (XML) — 338KB

Signatures

Signatures 30 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL Oragenics, Inc. Condensed Consolidated Balance Sheets March 31, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 2,071,989 $ 3,483,501 Prepaid expenses and other current assets 371,212 382,273 Total current assets 2,443,201 3,865,774 Prepaid research and development expense 1,090,750 1,090,750 Operating lease right-of-use assets — 9,811 Total assets $ 3,533,951 $ 4,966,335 Liabilities and Shareholders' Equity Current liabilities: Accounts payable and accrued expenses $ 781,846 $ 1,475,667 Short-term notes payable 126,840 312,703 Operating lease liabilities - Current — 9,811 Total liabilities 908,686 1,798,181 Shareholders' equity: Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, - 0 - and - 0 - Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at March 31, 2024 and December 31, 2023, respectively 1,592,723 1,592,723 Common stock, $ 0.001 par value; 350,000,000 shares authorized and 4,480,693 and 3,080,693 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 4,480 3,081 Additional paid-in capital 209,697,149 207,790,604 Accumulated Deficit ( 208,669,087 ) ( 206,218,254 ) Total shareholders' equity 2,625,265 3,168,154 Total liabilities and shareholders' equity $ 3,533,951 $ 4,966,335 The accompanying notes to the condensed consolidated financial statements are an integral part of these statements. 3 Oragenics, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 For the Three Months Ended March 31, 2024 2023 Grant revenue $ — $ 17,024 Operating expenses: Research and development 663,414 1,672,576 General and administrative 1,796,689 1,249,263 Total operatin

View Full Filing

View this 10-Q filing on SEC EDGAR